Disease modifying treatment and elective surgery in rheumatoid arthritis: The need for more data

Annals of the Rheumatic Diseases

Volumn 63, Issue 5, 2004, Pages 602-603

  Jain, A ^a   Maini, R ^a   Nanchahal, J ^b  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INDOMETACIN; INFLIXIMAB; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; ELECTIVE SURGERY; HUMAN; INFECTION; INFECTION RISK; POSTOPERATIVE COMPLICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT CONTRAINDICATION;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMMUNICABLE DISEASES; HUMANS; POSTOPERATIVE COMPLICATIONS; SURGICAL PROCEDURES, ELECTIVE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1942468038     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.017640     Document Type: Article

References (10)

1. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Jain A, Witbreuk M, Ball C, Nanchahal J. Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am 2002;27:449-55.
3. Da Silva E, Doran MF, Crowson CS, O'Fallon WM, Matteson EL. Declining use of orthopedic surgery in patients with rheumatoid arthritis? Results of a long-term, population-based assessment. Arthritis Rheum 2003;49:216-20.
4. Grennan DM, Gray J, Loudon J, Fear S. Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60:214-17.
5. Moreland LW, Bucy RP, Weinblatt ME, Mohler KM, Spencer-Green GT, Chatham WW. Immune function in patients with rheumatoid arthritis treated with etanercept. Clin Immunol 2002;103:13-21.
6. Cope AP, Londei M, Chu NR, Cohen SBA, Elliott MJ, Maini RN, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest 1994;94:749-60.
7. Schrieber S, Campieri M, Colombel JF, van Deventer SJH, Feagan B, Fedorak R, et al. Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis 2001;16:1-11.
8. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 2003;48:3013-22.
9. Baghai M, Osmon DR, Wolk DM, Wold LE, Haidukewych GJ, Matteson EL. Fatal sepsis in a patient with rheumatoid arthritis treated with Etanercept. Mayo Clin Proc 2001;76:653-6.
10. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:2838-46.